Tag: nephrology

1. Both 10 and 20 mgs of IV ketorolac were found to be non-inferior to 30 mg IV for the emergency pain management of renal colic. 2. The rate adverse effects across the three cohorts was found to be similar. Evidence Rating Level: 1 (Excellent) Study Rundown: Renal colic is commonly encountered...
1. Stopping renin-angiotensin system inhibition in patients with advanced chronic kidney disease was associated with higher risk of mortality, major cardiovascular events, and lower risk of kidney replacement therapy. Evidence Rating Level: 2 (Good) Studies have shown that renin-angiotensin system inhibitors (RASi) are effective in delaying chronic kidney disease (CKD) progression. Angiotensin-converting...
Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas 1. Carboplatin, given through intracerebral, convection-enhanced delivery, may be a viable adjunct in recurrent high-grade glioma treatment. Evidence Rating Level: 1 (Excellent) Patients with glioblastomas (GBM), which will invariably recur despite maximal therapy, have a poor prognosis,...
1. Among patients with severe chronic kidney disease requiring an arteriovenous fistula for hemodialysis, abnormal digital-brachial index was found to be predictive of fistula patency. Evidence Level Rating: 2 (Good) Some patients with advanced chronic kidney disease (CKD) may require renal replacement therapies like hemodialysis (HD), at which point creation and...
Rosuvastatin therapy in people with HIV at intermediate cardiovascular risk does not decrease biomarkers of inflammation and immune activation 1. Among virologically suppressed persons with HIV at moderate risk of cardiovascular disease, daily administration of rosuvastatin did not lead to significant reductions in inflammatory markers. Evidence Rating Level: 1 (Excellent) Due to...
1. In patients with CKD, fixed low dose of erythropoietin provides similar efficacy outcomes, such as percentage of patients requiring transfusions, as titration-based dosing based on Hgb levels while decreasing cumulative dose of erythropoietin needed. Evidence Rating Level: 1 (Excellent) Chronic kidney disease (CKD) patients have parenchymal loss leading to decreased...
1. Non-calcium-based phosphate binders did not affect arterial stiffness or aortic calcification compared to placebo in moderate-to-severe chronic kidney disease. Evidence Rating Level: 1 (Excellent) Abnormal phosphate homeostasis is characteristic of chronic kidney disease, with hyperphosphatemia strongly associated with increased arterial stiffness secondary to calcification. Positive phosphate balance may contribute to...
1. Among those presenting with symptomatic nephrolithiasis, patients electing for trial of passage with medical expulsion therapy were more likely to receive a prescription for an opiate compared with those electing for early surgical intervention. Evidence Rating Level: 3 (Average) Despite a widespread reduction in the number of prescriptions for opioids...
1. Among patients with type 2 diabetes mellitus and chronic kidney disease being treated with canagliflozin, earlier reductions in albuminuria were associated with a decreased risk of adverse renal and cardiovascular outcomes. Evidence Level Rating: 2 (Good) In the past, post hoc analyses from clinical trials of RAAS inhibitors have shown...
Early surgical intervention for symptomatic renal and ureteral stones is associated with reduced narcotic requirement relative to trial of passage 1. Among those presenting with symptomatic nephrolithiasis, patients electing for trial of passage with medical expulsion therapy were more likely to receive a prescription for an opiate compared with those...